Federal Circuit court halts delisting of Jazz narcolepsy drug patent from the Orange Book
The US Court of Appeals for the Federal Circuit yesterday ordered a halt to the delisting of a key patent for Jazz Pharmaceuticals’ narcolepsy drug in the FDA’s Orange Book, reversing a Delaware district court judge’s decision last month to remove the patent from the Orange Book.
The case at hand involves Avadel CNS Pharmaceuticals, which has sought to delist one of Jazz Pharmaceuticals’ patents related to the method for distributing its blockbuster narcolepsy drug Xyrem as part of a restricted distribution system under its REMS.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters